Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Capecitabine in Advanced GI Cancers
NCT06065371Phase 1Recruiting
- Sponsor
- Henry Ford Health
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sacituzumab govitecan in gastrointestinal cancer, sponsored by Henry Ford Health. Primary endpoint: Recommended Phase 2 Dose at 18 months. Started Nov 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT06065371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065371.